Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × GI Cancers × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 433 Neoplasms 362 Breast Neoplasms 256 Colorectal Neoplasms 241 Neoplasm Metastasis 211 Melanoma 209 Leukemia, Myeloid, Acute 188 Multiple Myeloma 187 Pancreatic Neoplasms 179 Ovarian Neoplasms 178 Recurrence 171 Prostatic Neoplasms 156 Lymphoma, Non-Hodgkin 140 Stomach Neoplasms 132 Squamous Cell Carcinoma of Head and Neck 126 Lung Neoplasms 125 Lymphoma 121 Carcinoma, Hepatocellular 116 Carcinoma, Renal Cell 100 Triple Negative Breast Neoplasms 99 Leukemia, Lymphocytic, Chronic, B-Cell 98 Glioblastoma 96 Leukemia 93 Advanced Solid Tumor 91 Lymphoma, Large B-Cell, Diffuse 89 Small Cell Lung Carcinoma 88 Head and Neck Neoplasms 86 Advanced Solid Tumors 80 Endometrial Neoplasms 79 Myelodysplastic Syndromes 78

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07216560 2026-01-15

First-in-human Study of 7MW4911 in GI Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Recruiting

GI Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡